Cargando…
Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson’s disease: preliminary cost-consequence analysis of the PD COMM pilot randomised controlled trial
BACKGROUND: The PD COMM pilot randomised controlled trial compared Lee Silverman Voice Treatment (LSVT® LOUD) with standard NHS speech and language therapy (SLT) and a control arm in people with Parkinson’s disease (PwPD) with self-reported problems with voice or speech. This analysis compares costs...
Autores principales: | Scobie, Sarah, Jowett, Sue, Lambe, Tosin, Patel, Smitaa, Woolley, Rebecca, Ives, Natalie, Rick, Caroline, Smith, Christina, Brady, Marion C, Clarke, Carl, Sackley, Cath |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351093/ https://www.ncbi.nlm.nih.gov/pubmed/34372913 http://dx.doi.org/10.1186/s40814-021-00888-y |
Ejemplares similares
-
Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson’s disease: a pilot randomised controlled trial (PD COMM pilot)
por: Sackley, Catherine M., et al.
Publicado: (2018) -
Lee Silverman voice treatment versus standard NHS speech and language therapy versus control in Parkinson’s disease (PD COMM pilot): study protocol for a randomized controlled trial
por: Sackley, Catherine M, et al.
Publicado: (2014) -
A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson’s disease: a study protocol for a randomised controlled trial
por: Sackley, C. M., et al.
Publicado: (2020) -
Feasibility and Acceptability of Lee Silverman Voice Treatment in Progressive Ataxias
por: Lowit, Anja, et al.
Publicado: (2020) -
Lee Silverman Voice Treatment to Improve Speech in Parkinson's Disease: A Systemic Review and Meta-Analysis
por: Pu, Tingting, et al.
Publicado: (2021)